

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

东曜药业

TOT BIOPHARM International Company Limited

東曜藥業股份有限公司

(Incorporated in Hong Kong with limited liability)

(Stock code: 1875)

CERTAIN UNAUDITED FINANCIAL INFORMATION FOR THE YEAR ENDED 31 DECEMBER 2022

This announcement is made by TOT BIOPHARM International Company Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) pursuant to Rule 13.09(2) of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Listing Rules**”) and the Inside Information Provisions (as defined under the Listing Rules) under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

Pursuant to applicable disclosure requirements of the Taipei Exchange in Taiwan, Center Laboratories, Inc. (the Company’s substantial shareholder holding over 20% of the Company’s issued share capital, whose shares are listed on the Taipei Exchange in Taiwan) is required to disclose, on a date which is expected to be on or before 17 March 2023, certain unaudited consolidated financial information of the Group for the year ended 31 December 2022. Such date of disclosure is earlier than 23 March 2023, being the expected date of publication of the Company’s 2022 annual results announcement containing the audited consolidated financial information of the Group for the year ended 31 December 2022.

In order to facilitate timely dissemination of information to investors and potential investors in Hong Kong and Taiwan, the Company’s board of directors (the “**Board**”) would like to inform the Company’s shareholders and potential investors of the following unaudited consolidated financial information of the Group for the year ended 31 December 2022, which is extracted from the Group’s latest unaudited management accounts and other information currently available.

IMPORTANT

As mentioned above, the Group's results for the year ended 31 December 2022 set out in this announcement are unaudited. The Group's results of operations in the past have fluctuated and may in the future continue to fluctuate from one period to another period. Accordingly, the Group's results of operations for any period should not be considered to be indicative of the results to be expected for any future period. Shareholders and potential investors of the Company are advised to exercise due care when dealing in the securities of the Company.

During the year ended 31 December 2022, the Group's revenue increased by 479% year-on-year to RMB442,178 thousand, mainly attributable to the substantial increase in sales of self-developed products, the continuous development of CDMO business and the increase in milestone payment income from licenses granted in connection with the Group's projects. In 2022, net loss recorded by the Group narrowed by 81% year-on-year to RMB50,046 thousand and its cash flow from operating activities became positive for the first time.

CONDENSED CONSOLIDATED BALANCE SHEET

	As at 31 December 2022 <i>RMB'000</i> (unaudited)	As at 31 December 2021 <i>RMB'000</i> (audited)
Current assets	676,797	305,963
Non-current assets	585,234	404,300
Current liabilities	(275,347)	(260,808)
Non-current liabilities	(271,245)	(114,364)
Total net assets	<u>715,439</u>	<u>335,091</u>

CONDENSED CONSOLIDATED STATEMENT OF COMPREHENSIVE LOSS

	For the year ended 31 December 2022 <i>RMB'000</i> (unaudited)	For the year ended 31 December 2021 <i>RMB'000</i> (audited)
Revenue	442,178	76,325
Net loss	(50,046)	(261,216)
Loss for the year and attributable to the equity holders of the Company	(49,916)	(261,216)
Other comprehensive income/(loss)	6,314	(956)
Total comprehensive loss for the year	<u>(43,732)</u>	<u>(262,172)</u>

The above information is subject to possible adjustments following further internal review and external audit, and is not based on any figure(s) or information which has/have been reviewed by the Company's external auditor or the Audit and Connected Transactions Review Committee. As mentioned above, the Company's 2022 annual results announcement containing the audited consolidated financial information of the Group for the year ended 31 December 2022 is expected to be published on 23 March 2023.

By order of the Board
TOT BIOPHARM International Company Limited
Dr. Liu, Jun
Chief Executive Officer and Executive Director

Hong Kong, 17 March 2023

As at the date of this announcement, the executive director of the Company is Dr. Liu, Jun; the non-executive directors of the Company are Mr. Fu, Shan, Ms. Yeh-Huang, Chun-Ying and Mr. Qiu, Yu Min; and the independent non-executive directors of the Company are Ms. Hu, Lan, Mr. Chang, Hong-Jen and Dr. Wang, De Qian.